SERUM OR PLASMA MICRORNA AS BIOMARKERS FOR NON-SMALL CELL LUNG CANCER
    12.
    发明申请
    SERUM OR PLASMA MICRORNA AS BIOMARKERS FOR NON-SMALL CELL LUNG CANCER 有权
    血清或血浆MICRORNA作为非小细胞肺癌的生物标志物

    公开(公告)号:US20110117565A1

    公开(公告)日:2011-05-19

    申请号:US12996967

    申请日:2009-12-14

    IPC分类号: C12Q1/68

    摘要: The present invention provides non-small cell lung cancer markers and the use thereof. The non-small cell lung cancer markers in the present invention include at least one of the 26 selected detectable mature microRNAs existing stably in human serum or plasma. The invention also provides a probe combination, kit and biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting microRNAs in the serum of lung cancer patients. By detecting the variations of microRNAs in the serum of lung cancer patients, the disease can be diagnosed in vitro; the progression course of the disease can be predicted; the occurrence of complications, the rate of relapse and the prognosis of the disease can be monitored; the drug efficacy and therapeutic effects can be analyzed. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of the low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases, all of which make it an effective means for diagnosing diseases at an early stage.

    摘要翻译: 本发明提供非小细胞肺癌标志物及其用途。 本发明中的非小细胞肺癌标志物包括稳定存在于人血清或血浆中的26种选择的可检测的成熟微RNA中的至少一种。 本发明还提供了用于检测非小细胞肺癌标志物的探针组合,试剂盒和生物芯片。 本发明还提供了一种检测肺癌患者血清中微小RNA的方法。 通过检测肺癌患者血清中microRNAs的变化,可以在体外诊断该疾病; 可以预测疾病的进展过程; 可以监测并发症的发生,复发率和预后; 可以分析药物的疗效和治疗效果。 本发明的方法能够广泛的检测光谱,高灵敏度,低成本,便于取样和保存。 该方法可应用于疾病综合调查,解决了以前单个标记物所遇到的低特异性和敏感性问题,并大大增加了疾病的临床检出率,这些都成为早期诊断疾病的有效手段 阶段。